Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
- Market Cap ₹ 5,567 Cr.
- Current Price ₹ 556
- High / Low ₹ 604 / 445
- Stock P/E 161
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 9.56 %
- ROE 7.29 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company's working capital requirements have reduced from 78.7 days to 61.9 days
Cons
- Promoter holding has decreased over last quarter: -15.2%
- Company has a low return on equity of 1.79% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 284 | 317 | 386 | 436 | 544 | |
| 247 | 299 | 348 | 384 | 449 | |
| Operating Profit | 38 | 18 | 38 | 52 | 95 |
| OPM % | 13% | 6% | 10% | 12% | 17% |
| 5 | 4 | 5 | 8 | 16 | |
| Interest | 7 | 10 | 15 | 17 | 14 |
| Depreciation | 34 | 39 | 41 | 43 | 51 |
| Profit before tax | 1 | -28 | -13 | 0 | 45 |
| Tax % | 22% | -22% | 20% | -1,668% | 25% |
| 1 | -22 | -15 | 4 | 34 | |
| EPS in Rs | 5.57 | -110.19 | -77.01 | 18.76 | 164.24 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | 767% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 2% |
| Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 |
| Reserves | 246 | 407 | 392 | 399 | 537 |
| 140 | 119 | 200 | 182 | 127 | |
| 32 | 45 | 54 | 82 | 92 | |
| Total Liabilities | 419 | 572 | 647 | 665 | 757 |
| 159 | 167 | 169 | 219 | 234 | |
| CWIP | 0 | 2 | 3 | 1 | 4 |
| Investments | 47 | 110 | 148 | 149 | 212 |
| 212 | 293 | 328 | 297 | 306 | |
| Total Assets | 419 | 572 | 647 | 665 | 757 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 33 | 12 | 11 | 57 | 80 | |
| -64 | -167 | -75 | -23 | -104 | |
| 36 | 147 | 63 | -36 | 26 | |
| Net Cash Flow | 4 | -8 | -0 | -1 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 98 | 106 | 122 | 116 | 130 |
| Inventory Days | 65 | 50 | 61 | 51 | 43 |
| Days Payable | 56 | 52 | 40 | 108 | 150 |
| Cash Conversion Cycle | 107 | 104 | 143 | 59 | 23 |
| Working Capital Days | 21 | 48 | 116 | 58 | 62 |
| ROCE % | -4% | 0% | 3% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
12 Feb - Subsidiary acquired Laurel, Batangas dialysis center assets for PHP 49,400,000 under ATA dated Feb 12, 2026.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
12 Feb - Crisil monitoring report: Rs3,534.05m IPO; Rs904.99m utilized; Rs2,629.06m unutilized as of Dec 31, 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Feb - Uploaded Feb 11, 2026 audio of investors' conference call on Q3 and 9M FY26 results.
- Announcement under Regulation 30 (LODR)-Investor Presentation 10 Feb
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Feb - Q3 revenue ₹259.7cr (31.7% YoY); 9M revenue ₹733.2cr (36.6%); EBITDA and PAT grew significantly.
Business Profile[1]
Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.